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https://doi.org/10.1016/j.celrep.2020.108050SUMMARYInteractome maps are valuable resources to elucidate protein function and disease mechanisms. Here, we
report on an interactomemap that focuses on neurodegenerative disease (ND), connects5,000 human pro-
teins via 30,000 candidate interactions and is generated by systematic yeast two-hybrid interaction
screening of 500 ND-related proteins and integration of literature interactions. This network reveals inter-
connectivity across diseases and links many known ND-causing proteins, such as a-synuclein, TDP-43,
and ATXN1, to a host of proteins previously unrelated to NDs. It facilitates the identification of interacting pro-
teins that significantly influencemutant TDP-43 and HTT toxicity in transgenic flies, as well as of ARF-GEP100
that controls misfolding and aggregation of multiple ND-causing proteins in experimental model systems.
Furthermore, it enables the prediction of ND-specific subnetworks and the identification of proteins, such
as ATXN1 and MKL1, that are abnormally aggregated in postmortem brains of Alzheimer’s disease patients,
suggesting widespread protein aggregation in NDs.INTRODUCTION
Neurodegenerative diseases (NDs), such as Alzheimer’s disease
(AD), Parkinson’s disease (PD), Huntington’s disease (HD),
amyotrophic lateral sclerosis (ALS), and frontotemporal demen-
tia (FTD), are seriously disabling, chronic disorders that put an
enormous burden on patients, caregivers, and health systems
(Goedert, 2015; Ross et al., 2014; Taylor et al., 2016). Disease-
modifying treatments are urgently needed; existing therapies
target symptoms in the late stages of disease, when pathology
is already advanced and relief is modest (Bawa et al., 2016).
To find effective treatments, it is of critical importance to under-
stand the underlying molecular mechanisms responsible for
onset and progression of NDs (Keiser et al., 2016; Khanam
et al., 2016).This is an open access article under the CC BY-NDecades of research have revealed commonalities between
inherited and sporadic NDs (Ling et al., 2013). This includes
overlapping clinical symptoms, pathway perturbations, and
pathogenic molecular mechanisms, like aggregation of dis-
ease-relevant proteins (Higashi et al., 2007; Rubinsztein, 2006).
Databases and network models have been created that enable
the identification of relevant pathways, common genetic modi-
fiers (Chen and Burgoyne, 2012; Khurana et al., 2017; Na et al.,
2013), and proteins linked to known ND-associated proteins
(Lim et al., 2006; Limviphuvadh et al., 2007).
The deposition of misfolded proteins in inclusion bodies or
amyloid plaques, both inside and outside of neuronal and glial
cells, is a pathological hallmark of more than 15 NDs, including
AD, PD, FTD, ALS, and polyglutamine (polyQ) disorders such




OPEN ACCESSmain protein component of pathological aggregates is specific
to each disease, such as a-synuclein (SNCA) in PD, huntingtin
(HTT) in HD, and b-amyloid in AD, several pathogenic proteins
are known to misfold and aggregate in more than one disease.
Abnormal aggregation of the RNA binding protein TDP-43 is
observed in FTD, ALS, and several further conditions (Chen-Plot-
kin et al., 2010; Toyoshima and Takahashi, 2014). Similarly, the
anomalous aggregation and deposition of SNCA and tau is a
pathological phenomenon detectable in brains of patients with
AD, PD, HD, and dementia with Lewy bodies (Gratuze et al.,
2016; Jellinger, 2012). This overlap in protein pathology supports
the hypothesis that neuronal dysfunction and degeneration in
various NDs are caused by shared pathomechanisms (Ling
et al., 2013). This view is substantiated by more recent discov-
eries indicating that amyloid aggregates from b-amyloid, tau,
HTT, SNCA, and TDP-43 polypeptides are biologically active
structures that can self-replicate and spread from cell to cell
by a prion-like mechanism (Brettschneider et al., 2015; Soto,
2012). Such corruptive aggregation templates, often termed
seeds, might function as drivers of pathogenesis in various NDs.
Studies of protein-protein interactions (PPIs) have demon-
strated that size, shape, and physicochemical complementar-
ities are critical determinants of protein complex formation
(Pechmann et al., 2009). Hydrophobic and electrostatic interac-
tions are further driving forces of aberrant protein aggregation
(Tartaglia et al., 2008). Identifying and characterizing PPIs can
therefore provide valuable knowledge on the formation of aber-
rant protein aggregates and the cellular processes that control
them. The aggregation propensity of ND-associated proteins
such as HTT is influenced dramatically by interactions with other
proteins (Stroedicke et al., 2015). PPIs either accelerate or slow
aggregation kinetics, thereby influencing toxicity of disease-
causing proteins in model systems (Mogk and Bukau, 2017;
Morley et al., 2002).
To identify connections between proteins, quantitative affinity
purification/mass spectrometry (MS)-based methods (Hosp
et al., 2015) or yeast-two-hybrid (Y2H) assays (Arumughan
et al., 2016; Goehler et al., 2004) are of high utility. They can
detect not only high-affinity PPIs but also weak, transient inter-
actions (Hein et al., 2015). These may have particular relevance
when aggregation-prone proteins are studied, because these
are often intrinsically disordered (Uversky et al., 2008) and bind
only weakly to partner proteins (Shimizu and Toh, 2009). Disor-
dered proteins, widespread in the human proteome (Pentony
and Jones, 2010; Uversky et al., 2008), are enriched among
known ND-associated proteins (Raychaudhuri et al., 2009), sug-
gesting that as a group they may play crucial roles in ND
processes.
Recent theoretical investigations indicate that a large fraction
of the proteins in the human proteome are vulnerable to misfold-
ing and aggregation because their cellular concentrations
relative to their solubilities are high (Ciryam et al., 2013, 2015).
These supersaturated or metastable proteins are overrepre-
sented in pathways perturbed in NDs (Ciryam et al., 2013).
Many proteins besides the known ones (HTT, SNCA, tau, TDP-
43, etc.) may therefore be aberrantly aggregated in disease
brains. They need to be identified to assess their relevance for
pathogenesis.2 Cell Reports 32, 108050, August 18, 2020In this study, we performed a systematic Y2H interaction
screen and integrated publicly available interaction data to
generate a high-confidence interactome map (5,000 proteins
connected via 30,000 candidate interactions) for ND-associ-
ated human proteins. Our network uncovers interconnectivity
across NDs and links known ND-causing proteins (NDCPs),
such as SNCA, TDP-43, and ataxin-1 (ATXN1), to proteins previ-
ously believed to be unrelated to NDs. It facilitated the identifica-
tion of interacting proteins that significantly influence mutant
TDP-43 and HTT toxicity in transgenic fly models. Furthermore,
it enabled the detection of the protein ARF-GEP100 that controls
misfolding and aggregation ofmultiple disease proteins in exper-
imental models. Finally, disease-specific subnetworks of AD,
PD, and ALS (ADSN, PDSN, and ALSSN) were predicted and pro-
teins such as MKL1 and ATXN1 were found to be aggregated in
AD postmortem brain tissue. Our focused interactome map
provides a powerful framework for elucidating the underlying
mechanisms of multiple NDs.
RESULTS
Selection of Bait Proteins and Automated Interaction
Screening
We used manually and computationally generated gene lists to
prioritize human protein-encoding genes for their association
with NDs such as AD, PD, ALS, HD, and SCA1 (Figure 1A;
Table S1). By systematically extracting and combining infor-
mation on diseases from available public databases and
PubMed abstracts (Fontaine et al., 2009, 2011), a ranked list
of 3,711 genes with a potential role in NDs was generated
(Table S1). The 100 top-ranking genes include many well-
known ND genes, such as SNCA, MAPT, APP, HTT, and
ATXN1. These genes, when mutated, cause early-onset, in-
herited NDs with severe symptoms (Gatchel and Zoghbi,
2005; Taylor et al., 2016). Importantly, a fraction of the top
100 genes have not been studied extensively in the context
of NDs so far (Figure S1; Table S1).
To identify interaction partners for proteins involved in multiple
NDs, an automated Y2H system was applied, which allows the
detection of binary PPIs through systematic interaction mating
(Stelzl et al., 2005; Vinayagam et al., 2011). We focused on the
first 524 open reading frames (ORFs) from the ranked list. They
were subcloned as full-length cDNAs or fragments thereof into
bait expression plasmids using the Gateway technology. We
generated 596 MATa yeast strains that produce DNA binding
domain fusion proteins (baits), of which 492 (82.6%) (Table S1)
produced non-autoactivating bait proteins and were suitable
for interaction mating. Subsequently, all MATa strains were
screened as pools against an array of 16,000 MATa yeast
strains expressing prey proteins. Positive clones, which activate
the reporters HIS3, URA3, and lacZ, were identified by growth
selection on selective plates and b-galactosidase assays (Fig-
ure 1B). To increase our sampling, the entire search space
was independently screened four times. Putative interactions
identified in the pooled mating experiments were subsequently
retested in multiple pairwise experiments. The steps of the








Figure 1. Research Approach and Workflow of the Interactome Mapping Study
(A) Selection of ND-associated target proteins for interaction mapping studies using available literature information.
(B) Identification of interaction partners for selected target proteins by automated Y2H interaction screening.
(C) Integration of identified Y2H interactions with published binary PPIs to create an extended interactome network for proteins involved in NDs.
(D) Validation of selected binary PPIs with computational and experimental methods.
(E) Computational prediction of subnetworks and protein modules for AD, PD, and ALS starting from NN1.0ext and known NDCPs.
(F) Analysis of the potential disease relevance of selected proteins from computationally predicted ND modules using experimental model systems and patient
brain samples.
See also Tables S1, S2, S3, S4, S5, and S6 and Figures S2 and S4–S6.
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OPEN ACCESSUsing this experimental approach, we identified 18,663
Y2H candidate interactions connecting 471 bait and 3,482
prey proteins. For further analysis of PPI data, each cDNA frag-
ment was mapped to the Entrez GeneID and a final dataset—
termed NeuroNet1.0 (NN1.0)—was created. It connects 3,135
unique human proteins via 13,736 Y2H PPIs (Table S2). A com-
parison of the NN1.0 data with literature interactions in the HIP-
PIE (Human Integrated Protein–Protein Interaction rEference)
database (Alanis-Lobato et al., 2017) revealed that only 783
(5.7%) of the identified PPIs are already known.Extension of NN1.0 andComputational Validation of Y2H
Interactions
Because previous investigations with positive PPI reference sets
have demonstrated that the sensitivity of Y2H assays is 25%
(Venkatesan et al., 2009), it is advisable to combine high-confi-
dence binary interaction datasets to augment the scope and
density of interactome network maps. To expand NN1.0 (Fig-
ure 1C), we added high-quality binary interactions from the Lit-
BM-13 and HI-II-14 datasets (Rolland et al., 2014). Using this
strategy, we created NeuroNet1.0extended (NN1.0ext) thatCell Reports 32, 108050, August 18, 2020 3
A
C D
B Figure 2. Functional and Disease Rele-
vance of Binary Interactions in NN1.0 and
NN1.0ext
(A) Enrichment of binary interactome maps
(NN1.0, NN1.0ext, and HI-II-14) for functional
relationships and cocomplex memberships.
Literature interactions were obtained from previ-
ous publications and databases: HI-II-14, binary
interactome dataset; MS, MS-based map; Phos-
phosite, kinase-substrate interactions; CORUM,
protein complex dataset.
(B–D) Prediction of known NDCPs, ND modifiers,
and drug targets in NN1.0ext using network
propagation. Prediction performance is measured
using a ROC curve (red); predictions were
compared with those of 100 randomized networks
that preserve node degrees (gray) and the random
expectation (dashed black).
See also Table S3.
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OPEN ACCESSeither directly connects NN1.0 proteins or links Lit-BM-13 and
HI-II-14 proteins to NN1.0 proteins (Figure S2B) via at least two
interactions. NN1.0ext links 4,956 human proteins via 30,374
candidate interactions (Table S2).
Next, we performed a computational assessment of the qual-
ity of the interactions in NN1.0 and NN1.0ext. The high-quality
PPI dataset HI-II-14 (Rolland et al., 2014) was analyzed as a con-
trol. We first measured enrichment for shared Gene Ontology
(GO) terms for biological process (BP), molecular function (MF),
and cellular component (CC). We observed significant enrich-
ment for BP and CC terms in all three datasets (Figure 2A). For
MF, significant enrichment was observed for NN1.0 and
NN1.0ext, but not for HI-II-14. Then, we determined how many
binary interactions are part of larger protein complexes as anno-
tated in CORUM (protein complex data set) (Ruepp et al., 2010)
and MS (Woodsmith and Stelzl, 2014), a MS-based interaction
dataset. We observed similar performance of the PPIs from all
three datasets (Figure 2A). Finally, we investigated the overlap
of the interactions in the three datasets with kinase-substrate in-
teractions cataloged in Phosphosite (Hornbeck et al., 2015). We
found that interactions from both NN1.0 and NN1.0ext, but not
from HI-II-14, were enriched, indicating that the ND-focused da-
tasets contain known kinase-substrate interactions. Overall,
these results support the assumption that NN1.0 and NN1.0ext
contain biologically meaningful interactions.
Finally, we assessed the network’s relevance for known
NDCPs, such as SNCA, HTT, and TDP-43. In NN1.0ext, 2,173
proteins are linked to 94 known NDCPs (Tables S2 and S3). 62
NDCPs are connected via 85 direct interactions (Figure S2C),
suggesting that NDs are linked at the molecular level. Using a
cross-validation setting, we assessed the ability of NN1.0ext to
predict novel proteins relevant for ND. Starting from curated
sets of (1) NDCPs, (2) known ND modifiers, and (3) drug targets4 Cell Reports 32, 108050, August 18, 2020(Table S3), we used a network propaga-
tion algorithm (Vanunu et al., 2010) to
predict ND-related proteins. For compar-
ison, the same procedure was applied to
100 randomized networks with the samenode degree distribution. Receiver operating characteristic
(ROC) curve analysis revealed that NN1.0ext is suited to predict
NDCPs, ND modifiers, and drug targets (Figures 2B–2D; empir-
ical p < 0.01).
Experimental Validation of Interactions
For experimental validation (Figure 1D), Y2H interactions were
retested in a dual luminescence-based coimmunoprecipitation
(DULIP) assay in mammalian cells (Trepte et al., 2015). We
first assessed the performance of the method with two refer-
ence sets, one with known low-affinity PPIs (dissociation con-
stant Kd > 107 M; L-Aff reference set), another with known
high-affinity PPIs (Kd < 107 M; H-Aff reference set). In addi-
tion, the reference sets hsPRS-v1 and hsRRS-v1 (Braun
et al., 2009) were investigated. We detected PPIs in the refer-
ence sets L-Aff and H-Aff with success rates of 26.5% and
39.1%, respectively (Figure 3A; Table S4), substantiating pre-
vious observations that coimmunoprecipitation methods have
a preference for high-affinity interactions (Elion, 2006). In com-
parison, PPIs in the reference sets hsPRS-v1 and hsRRS-v1
were identified with success rates of 30.5% and 3.8%,
respectively (Figure 3A; Table S4), confirming that the method
is suited to distinguishing between positive and negative inter-
actions (Trepte et al., 2015). Next, we applied the DULIP
method to independently validate 231 randomly selected
PPIs from the NN1.0ext dataset, of which 169 (73.2%) were
NN1.0 PPIs. We confirmed the NN1.0 interactions with a suc-
cess rate of 23.1% (39 PPIs), whereas the interactions from
the HI-II-14 dataset (62 PPIs) were detected with a success
rate of 25.8% (16 PPIs). Altogether, we confirmed Y2H interac-
tions in NN1.0ext with a success rate of 23.8% (55 PPIs) (Fig-
ure 3A; Table S4), indicating that the data can be verified with





B Figure 3. Experimental Validation of Interac-
tions in DULIP Assays and Disease Model
Systems
(A) Validation of binary Y2H PPIs in mammalian cells
using DULIP. The recovery of binary interactions by
DULIP from several PPI sets was investigated. The
statistical significance was assessed using a Fisher’s
exact test with Holm-Bonferroni correction (***p <
0.001, ****p < 0.0001).
(B) RNAi screen as an orthologous approach to
assess the functional significance of TDP-43 in-
teractions. PPIs from the NN1.0ext dataset (Y2H) and
a published affinity-purification-based MS dataset
were assessed with systematic RNAi knockdown
experiments in a D. melanogaster disease model
(Ritson et al., 2010).
(C) Selected eye phenotypes resulting from RNAi
knockdown experiments in transgenic flies express-
ing the mutant protein TDP-43-M337V in photore-
ceptors (Ritson et al., 2010). Both phenotype
enhancing and phenotype suppressing effects can be
observed.
(D) Selected eye phenotypes resulting from over-
expression of human HTT partner proteins in a
D. melanogaster HD model. Expression of the mutant
protein HTT336Q128 leads to a severe eye phenotype
(Stroedicke et al., 2015) that can be modified by HTT-
interacting proteins.
(E) Quantification of retinal degeneration in HD
transgenic flies (Stroedicke et al., 2015). n R 9 flies
per genotype; data are represented as mean ± SEM;
***p % 0.001, two-sided t test with unequal variance.
Red, suppressors; green, enhancers.
See also Table S4.






OPEN ACCESSTo investigate whether the Y2H interactions identified in
this study are of functional relevance, we performed systematic
RNA interference (RNAi) knockdown experiments in a
Drosophila melanogaster model that expresses a TDP-43 pro-
tein with the M337V mutation (Ritson et al., 2010). In humans,
this mutation causes highly penetrant familial ALS (Sreedharan
et al., 2008); in transgenic flies, expression of TDP-43-M337V
leads to a moderate degenerative eye phenotype (Ritson
et al., 2010).
We hypothesized that decreasing the abundance of biologi-
cally relevant TDP-43 interaction partners in TDP-43-M337V-
expressing transgenic flies with RNAi might reveal disease-rele-
vant functional interactions. We obtained RNAi lines (Dietzl et al.,
2007) for 77 TDP-43 interaction partners (Table S4) identified in
Y2H screens and crossed these lines with transgenic TDP-43-
M337V flies. Then, the impact of gene knockdowns on the
rough-eye phenotype was systematically analyzed. For most
genes, we investigated the effect of two independent RNAi lines
(Table S4). Finally, fly strains were classified according to the
impact of the short hairpin RNAs (shRNAs) (no effect, weak
effect, or strong effect). Of 77 genes tested in flies, 47 (61%)
influenced the phenotype (Figures 3B and 3C). Knockdown of
12 genes (15.6%) had a strong effect on the TDP-43-M337V-
mediated eye phenotype. These results are in good agreement
with previous studies, indicating that modifier genes are
identified with a success rate of45%when interaction partners
of a specific target protein are assessed with focused RNAi
experiments in transgenic flies (Kaltenbach et al., 2007). In com-
parison, in a large-scale RNAi knockdown screen in Drosophila,
genetic modifiers were detected with a hit rate of 7.5% (Lam-
itina et al., 2006; Sigoillot and King, 2011). Strikingly, our studies
revealed that knockdown of the nuclear RNA export protein
NXF1 strongly suppresses the TDP-43-M337V-mediated eye
phenotype (Figure 3C), supporting recent observations that
inhibiting TDP-43 translocation from the nucleus into the cyto-
plasm is a protective strategy (Archbold et al., 2018).
Similar results were obtained when the knockdown of TDP-43
interaction partners previously identified by affinity purification
and MS (Freibaum et al., 2010) was analyzed in transgenic flies.
We selected 78 TDP-43-interacting proteins from published data
for gene knockdown experiments in TDP-43-M337V flies, of
which 19 (24.4%) were also identified as TDP-43 partners in
this Y2H study (Figure S3A). 55 of the genes (70.5%) influenced
the rough-eye phenotype (Figures 3B and 3C). In total, the
impact of 136 genes (Table S4) was systematically tested in
the transgenic fly model, of which 85 genes (62.5%) influenced
the TDP-43-M337V-induced rough-eye phenotype (Figures 3B,
3C, and S3B; Table S4). Knockdown of 59 genes (69.4%)
enhanced the phenotype; knockdown of 26 genes (30.6%) sup-
pressed it.
Next, the effect of interaction partners on the subcellular
localization of a YFP (yellow fluorescent protein)-tagged TDP-
43-M337V fusion protein was assessed in a Caenorhabditis
elegansmodel.We randomly selected 15TDP-43-interacting pro-
teins from the Y2H interaction dataset, of which 17 orthologous
genes (Table S4) were ultimately assessed in RNAi experiments
(Nollen et al., 2004). We defined three phenotypes to study the
gene knockdown effects on TDP-43-M337V-YFP localization:6 Cell Reports 32, 108050, August 18, 2020(1) exclusively nuclear localization (no effect), (2) nuclear localiza-
tion plus the appearance of cytoplasmic TDP-43 protein (weak
effect), and (3) nuclear localization plus cytoplasmic foci and
diffuse cytoplasmic staining (strong effect). We found that knock-
down of 7 (41.2%) of 17 tested genes alters the localization of
TDP-43-M337V-YFP in C. elegans (Figure S3C; Table S4).
Finally, we assessed whether coexpression of HTT-interacting
proteins canmodulate a severe degenerative eye phenotype in a
transgenic D. melanogaster HD model (Kaltenbach et al., 2007;
Stroedicke et al., 2015). We generated 35 fly strains that copro-
duce HTT-interacting proteins and an N-terminal HTT fragment
with a pathogenic polyQ tract of 128 glutamines (HTT336Q128)
and investigated the degeneration of photoreceptors in flies
(Stroedicke et al., 2015). We found that 17 (48.6%) of 35 investi-
gated human proteins significantly influence the HTT336Q128-
induced eye phenotype (Figures 3D and 3E; Table S4), of which
10 (58.8%) suppressed and 7 (41.2%) enhanced the phenotype.
Collectively, these experiments indicate that genetic modifiers
are enriched in the PPI dataset.
Prediction of ND-Focused Protein Subnetworks and
Cross-Validation with Reported Datasets
Previous work has shown the utility of network-based ap-
proaches in predicting potentially disease-relevant subnet-
works and protein modules (Barabási et al., 2011). To define
ND-specific protein subnetworks in NN1.0ext, we applied a
computational method for associating protein complexes with
ND phenotypes (Mazza et al., 2016). We first scored proteins
in NN1.0ext based on their proximity to a set of prior proteins,
which we predefined based on their causative role in inherited
NDs. We focused on AD, PD, and ALS, for which many NDCPs
have been reported (Lill, 2016; Rosenberg et al., 2016; Taylor
et al., 2016). Through network propagation (Cowen et al.,
2017; Vanunu et al., 2010), ranked lists of network proteins
were created (Figure S4A; Table S5). For each disease, the re-
sulting propagation scores were compared with scores from
random controls, which were obtained with random protein
sets of the same size as the set of disease-causing proteins.
Proteins with significantly high scores (p < 0.01) were used to
create the disease subnetworks ADSN, PDSN, and ALSSN, which
contain 738, 285, and 283 human proteins (Table S5), respec-
tively. The subnetwork ALSSN is exemplarily shown in Fig-
ure S4B. It contains 13 known ALS-associated NDCPs that
were initially used as priors for network propagation (Fig-
ure S4C), as well as 59 further known disease-associated pro-
teins referenced in OMIM (OMIM disease-associated proteins
[ODAPs]) (Amberger et al., 2015). Similarly, the subnetworks
ADSN and PDSN contain NDCPs (Figure S4C), along with
numerous ODAPs (Figure S4D).
Next, we performed cross-validation using two datasets with
reported genetic modifiers (Chen and Burgoyne, 2012; Na
et al., 2013) that influence ND-associated phenotypes in model
systems such as Drosophila, C. elegans, and yeast. To identify
modifiers that potentially influence pathogenesis in different
NDs, we compiled the predicted proteins in ADSN, PDSN, and
ALSSN and cross-compared the generated protein list with
the reported datasets (Na et al., 2013; Chen and Burgoyne,








Figure 4. Computationally Predicted ND
Subnetworks and Modules
(A) Cross-comparison of computationally pre-
dicted proteins in ADSN, PDSN, and ALSSN with
datasets of potential genetic modifiers reported in
Na et al. (2013) and Chen and Burgoyne (2012).
The Venn diagram indicates the number of genetic
modifiers recovered.
(B) Statistical analysis of data cross-comparisons.
The calculated hypergeometric p values for the
recovered genetic modifiers in (A) are shown.
(C) Ingenuity pathway analysis (IPA) with 21 po-
tential genetic modifiers identified by data cross-
comparison shown in (A).
(D–F) Disease protein modules containing inter-
connected high-scoring protein clusters for the
diseases AD, PD, and ALS are shown. Known
NDCPs, marked in purple, were used as a starting
point (priors) for network propagation. Other
known ODAPs are marked in gray. Other colors
indicate highly connected protein clusters.
(G) Representation of priors (known NDCPs) in the
predicted modules.
(H) Representation of other known ODAPs (based
on available OMIM data) in the predicted modules.
See also Table S5 and Figure S4A.
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OPEN ACCESS(Figures 4A and 4B), indicating that potential disease modifiers
are present in the computationally predicted subnetworks. 21
proteins were identified in all three datasets (Figure 4A), suggest-
ing that at least a fraction of the predicted ND-associated
proteins are common disease modifiers. Many proteins initially
found as genetic modifiers in HD model systems are also linked
to AD pathogenesis (Table S5). For example, the ribosomal pro-
teins L18 and L19 were found in all three predicted subnetworks
(Table S5), hinting at an important role of ribosome function an-
d/or protein translation in different NDs. In addition, Hsp40
(DNAJB4) was identified in all three subnetworks (ADSN, PDSN,
and ALSSN) (Table S5), supporting previous studies that chaper-
ones safeguard proteostasis in different NDs (Brehme et al.,
2014). A potential disease-modifying role of protein translation
in NDs was confirmed by ingenuity pathway analysis (Thomas
and Bonchev, 2010), indicating that proteins involved in eukary-
otic Initiation Factor 2 (eIF2) signaling are enriched among the
potential ND-associated genetic modifiers (Figure 4C). Strik-
ingly, enhanced concentrations of stress kinases such as PKR
(protein kinase R) that phosphorylate eIF2 and thereby slow
translation have been observed in brains of ND patients (Bando
et al., 2005; Hugon et al., 2017).C




Using an algorithm, smaller protein clus-
ters were derived from the large subnet-
works that are more easily accessible
for experimental validation (Figure S4A).
The generated modules ADMO, PDMO,
and ALSMO contain 30, 28, and 27 pro-teins, respectively (Table S5). For each disease, the 4–5
highest-scoring interconnected protein clusters are displayed
(Figures 4D–4F). As expected, each module contains NDCPs
that were initially used as a starting point for the module identifi-
cation process (Figure 4G) as well as ODAPs (Figure 4H), which
were not used as priors (Figure 4H; hypergeometric p < 0.0001).
Certain known NDCPs were present in multiple ND-associ-
ated protein modules. For example, ATXN1, which is mutated
in SCA1 (Donato et al., 2012), was found both in ADMO and
ALSMO (Figures 4D and 4F), supporting previous observations
that ATXN1 is also associated with these diseases (Conforti
et al., 2012; Zhang et al., 2010). Similarly, we found that SNCA,
which in its mutated form causes familial PD (Xu et al., 2015),
is present in ADMO, PDMO, and ALSMO (Figures 4D–4F). Proteins
not previously associated with NDs, such as MKL1, a transcrip-
tional coactivator for the serum response factor (Scharenberg
et al., 2010), were linked to AD, PD, and ALS (Figures 4D–4F).
Loss of this protein was previously shown to decrease neurite
length in hippocampal neurons (Knöll et al., 2006). Similarly, we
observed that knockdown of Drosophila Mkl1 dramatically
enhances the TDP-43-M337V-mediated rough-eye phenotype
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OPEN ACCESSneurons (Kaneda et al., 2018). Many connections to known
NDCPswere also observed for the guanine nucleotide exchange
protein ARF-GEP100 (IQSEC1) (Figures 4E and 4F), which regu-
lates vesicle formation and phagocytosis in mammalian cells
(Someya et al., 2010).
ND-Associated Subnetworks Contain Proteins that
Aggregate in Patient Brains
Supersaturated proteins are metastable and have an elevated
aggregation propensity in mammalian cells (Ciryam et al.,
2013). Human proteins were previously classified according to
their supersaturation scores sf and su that measure the risk of
folded (sf) and unfolded (su) proteins to form insoluble aggre-
gates. Using these scores, aggregation-prone proteins were
predicted to be overrepresented among ND-associated proteins
(Ciryam et al., 2015), suggesting that such proteins might also be
enriched in disease subnetworks (Figure S4B; Table S5). We first
calculated the median su and sf supersaturation scores for
the proteins in ADSN, PDSN, and ALSSN (Table S5) and then
compared these values to the median score of the proteome.
We found that the sf scores for the network proteins were
significantly higher than those for the control proteins (Figure 5A),
indicating that aggregation-prone proteins are enriched in the
predicted subnetworks. The analysis of median su scores re-
vealed that unfolded proteins with a high aggregation propensity
are less abundant in disease subnetworks, except for ADSN (Fig-
ure 5B), which contains many proteins with high su scores.
Next, we assessed whether proteins that form abnormal ag-
gregates in brains of patients with NDs tend to appear in the
ND-associated subnetworks. We evaluated published proteo-
mic studies and assessed whether proteins found in amyloid
plaques (Liao et al., 2004), neurofibrillary tangles (NFTs) (Wang
et al., 2005) or Lewy bodies (Xia et al., 2008) are present in the
computationally predicted disease networks. We found that
117 (15.4%; hypergeometric p < 0.0001) of the 762 aggregated
proteins in AD and PD patient brains are present in the predicted
disease subnetworks (Figures 5C–5E), supporting our hypothe-
sis that aggregation-prone proteins are enriched among ND-
associated proteins.
Predicted ND Protein Modules Facilitate Identification
of Aggregated Proteins in AD Patient Brains
To investigate whether proteins in ADMO (Figure 4D) are abnor-
mally aggregated in disease, we analyzed postmortem brains
of AD patients and age-matched controls using a filter retarda-Figure 5. Computationally Predicted Proteins Are Abnormally Aggrega
(A and B) Comparison of supersaturation scores sf (A) and su (B) of proteins in th
extend from the lower to the upper quartiles, with the internal lines referring to the
U test with Bonferroni-corrected p values (*p < 0.05, **p < 0.01, ***p < 0.001, ****p <
median for the human proteome.
(C–E) Abundance of proteins found in aggregates of ND patient brains in ND-spec
proteins associated with NFTs, and (E) proteins identified in Lewy bodies. The s
ferroni corrections (*p < 0.05, ***p < 0.001, ****p < 0.0001). PL, plaques; LB, Lew
(F–O) Detection of insoluble protein aggregates in postmortem brain homogenate
red lettering) using a native FRA. Triplicates per sample were filtered. Quantifica
Aida image analysis software. The statistical significance was assessed with an
mean ± SEM.
See also Tables S5 and S6 and Figures S4B–S4D and S5.tion assay (FRA) (Wanker et al., 1999). We initially selected 15
proteins from ADMO for this analysis. Because of a lack of
specific antibodies, however (Table S6), we finally assessed
the aggregation state of 7 proteins in AD patient and control
brains (Figures 5H–5N and S5A). For benchmarking, we first
examined tau and TDP-43, which are aberrantly aggregated in
AD brains (Kr€uger and Mandelkow, 2016; Wilson et al., 2011).
Analysis of tissue homogenates (10 each, temporal cortex)
with FRAs revealed significantly higher levels of tau and TDP-
43 aggregates in AD samples than in controls (Figures 5F and
5G). Next, we analyzed the aggregation state of the predicted
proteins ATXN1, filamin A (FLNA), ubiquilin-1 (UBQLN1), Hsp70
(HSPA5), ERG2, SNCA, and MKL1 in brain homogenates using
the FRA. Except for SNCA (Kelley et al., 2018; Xu et al., 2002),
all selected proteins had previously not been described to form
abnormal aggregates in AD patient brains, whereas colocaliza-
tion of UBQLN1 and FLNA with tau aggregates was reported
(Feuillette et al., 2010;Mizukami et al., 2014). Strikingly, we found
that all proteins were significantly more strongly aggregated in
AD than in control brains (Figures 5H–5N), substantiating our
hypothesis that aggregation-prone proteins are associated
with NDs. The specificity of the applied antibodies was
confirmed by SDS-PAGE and immunoblotting (Figure S5A). No
aggregation was detected with the control protein actin (Fig-
ure 5O). Finally, we confirmed that high-molecular-weight
MKL1, ATXN1, UBQLN1, and FLNA aggregates can also be de-
tected in AD patient brains by native PAGE and immunoblotting
(Figures S5B–S5E).
ARF-GEP100 Controls Misfolding and Aggregation of
Multiple NDCPs
Many well-known NDCPs such as SNCA and TDP-43 have a
high propensity to self-assemble into insoluble protein aggre-
gates in NDs (Sami et al., 2017). We hypothesized that NDCP-
interacting proteins might control their aggregation propensity
in disease-relevant model systems. To address this question,
we focused on the protein ARF-GEP100 (IQSEC1) that interacts
with multiple aggregation-prone proteins such as TDP-43 and
SOD1 (Figures 4E and 4F; Table S5) in yeast and LuTHy assays
(Figure S6A). ARF-GEP100 is expressed in brain and was previ-
ously shown to regulate phagocytosis (Someya et al., 2010),
suggesting that it might influence the degradation of different
misfolded NDCPs in mammalian cells.
We first assessed whether RNAi-mediated knockdown of
the gene M02B7.5 (IQSEC1) in a C. elegans model influencested in Postmortem Brains of AD Patients
e proteome and proteins in the predicted ND-specific subnetworks. Boxplots
median values. The statistical significance was assessed by the Mann-Whitney
0.0001). FC, fold change; the values indicate supersaturation scores above the
ific subnetworks and the whole proteome. (C) Proteins found in AD plaques, (D)
tatistical significance was assessed with a Fisher’s exact test with Holm-Bon-
y bodies.
s of 10 AD patients (1–10, black lettering) and 10 age-matched controls (11–20,
tion of protein aggregates retained on filter membranes was performed using
unpaired, two-tailed t test (***p < 0.001, **p < 0.01). All data are expressed as
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Figure 6. ARF-GEP100 Influences Misfolding of Different Aggregation-Prone Polypeptides in Model Systems
(A) SYN-YFP aggregation phenotype resulting from RNAi-mediated knockdown of target genes in a transgenic C. elegans model. Representative images are
shown.
(B) Quantification of aggregates (green dots) shown in (A). n = 7–10 nematodes per knockdown experiment were analyzed. ***p < 0.001 by two-sided t test.
(C)Q35-YFPaggregationphenotype resulting fromRNAi-mediatedknockdownof target genes in a transgenicC.elegansmodel. Representative imagesareshown.
(D) Quantification of aggregates (green dots) shown in (C). n = 20 nematodes per knockdown experiment were analyzed. ***p < 0.001 by two-sided t test.
(E) Luciferase-R188Q-R216Q-YFP aggregation phenotype resulting from RNAi-mediated knockdown of target genes in a transgenic C. elegans model.
Representative images are shown.
(F) Quantification of aggregates (green dots) shown in (E). n = 20 worms per knockdown experiment were analyzed. ***p < 0.001 by two-sided t test.
(G) Effect of V5-tagged ARF-GEP100 coproduction on CFP-HTTex1Q49 aggregation in HeLa cells. Representative images of mutant HTT aggregates retained on
filter membranes (black dots) are shown.
(H) Quantification of results shown in (G). *p < 0.05 by two-sided t test.
Data in (B), (D), (F), and (H) are expressed as mean ± SEM.
See also Table S4 and Figures S3C–S3E and S6B–S6D.
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OPEN ACCESSa-synuclein-YFP (SYN-YFP) aggregation inmuscle cells. In addi-
tion, the knockdown of the hsp-1 gene, encoding the molecular
chaperone Hsc70 (Nollen et al., 2004), was assessed as a10 Cell Reports 32, 108050, August 18, 2020positive control. We observed a strong increase of SYN-YFP ag-
gregation upon knockdown of both genes (Figures 6A and 6B),
suggesting that ARF-GEP100, similar to Hsc70, controls
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OPEN ACCESSmisfolding and aggregation of SNCA in nematodes. The RNAi-
mediated knockdown of IQSEC1 transcripts in SYN-YFP-ex-
pressing worms was confirmed in two independent qRT-PCR
experiments (Figures S3D and S3E).
Next, we assessed whether knockdown ofM02B7.5 also influ-
ences polyQ-mediated protein aggregation (Scherzinger et al.,
1999) in worms. Expression of Q35-YFP in C. elegans leads to
the formation of proteotoxic aggregates in muscle cells, which
increase in their abundance upon RNAi-mediated knockdown
of hsp-1 (Morley et al., 2002; Nollen et al., 2004). We observed
that Q35-YFP aggregation was significantly increased in muscle
cells when M02B7.5 was knocked down (Figures 6C and 6D),
indicating that ARF-GEP100, similar to molecular chaperones
(Mogk and Bukau, 2017), influences aggregation of different
disease proteins in cells.
We also assessed whether knockdown of ARF-GEP100 influ-
ences aggregation of the folding sensor luciferase-R188Q-
R216Q-YFP (Rampelt et al., 2012) in worms. We found that this
protein is soluble in muscle cells under control conditions. How-
ever, it formed insoluble protein aggregates when the genes
M02B7.5 and hsp-1 were knocked down (Figures 6E and 6F).
Finally, we investigated whether overproduction of ARF-
GEP100 influences polyQ-mediated protein aggregation in
mammalian cells. We coexpressed ARF-GEP100 with a CFP-
tagged HTTex1Q49 fusion protein in HeLa cells and quantified
the formation of polyQ-containing protein aggregates after
24 h by FRA (Wanker et al., 1999). In a control experiment, the in-
fluence ofmCherryLuc onCFP-HTTex1Q49 aggregation was as-
sessed. We found ARF-GEP100 overproduction significantly
decreased the abundance of CFP-HTTex1Q49 aggregates in
mammalian cells (Figures 6G and 6H). The expression of tagged
recombinant proteins was confirmed by SDS-PAGE and immu-
noblotting (Figures S6B–S6D).
DISCUSSION
Screening for PPIs and integrating publicly available interaction
data, we generated an interactome network (termed NN1.0ext)
focused on proteins associated with various NDs, such as AD,
PD, and ALS. It directly connects 4,956 human proteins via
30,374 candidate interactions, providing a framework for
computational network-based interrogations (Barabási et al.,
2011) and more focused, hypothesis-driven experiments (Aru-
mughan et al., 2016).
In NN1.0ext, 1,348 partner proteins are linked to 94 well-
known NDCPs, such as TDP-43, SNCA, LRRK2, and HTT, indi-
cating that it contains relevant information for multiple NDs.
Focused interaction maps centered on specific proteins can
be extracted from the PPI data formore detailed functional anno-
tation of disease proteins. NN1.0ext also highlights connections
among NDCPs (Figure S2C), indicating that multiple relation-
ships exist among ND-associated molecules. For example, we
confirmed an interaction between the HD-causing protein HTT
and optineurin (OPTN), which is mutated in ALS (Maruyama
et al., 2010). Optineurin controls autophagy in mammalian cells
(Ying and Yue, 2016), and mutations in this protein are linked
to the accumulation of abnormal protein aggregates in brains
of ALS patients (Maruyama et al., 2010). Our results implicateoptineurin in HD and other NDs (Figure S2C), supporting previ-
ous evidence that it is a multifunctional adaptor with a role in
different NDs (Markovinovic et al., 2017).
A disease phenotype is rarely the consequence of an abnor-
mality in a single gene or protein but rather reflects a multitude
of pathobiological processes connected in a complex network
(Barabási et al., 2011). Starting from known NDCPs and the
NN1.0ext PPI dataset, we computationally predicted subnet-
works and interconnected protein modules for AD, PD and
ALS (Figures 4D–4F), which contain many proteins that had not
previously been linked to a specific disease. We propose that
disease-causing missense mutations in NDCPs perturb a
considerable number of disease-associated interactions, lead-
ing to neuronal dysfunction and neurotoxicity. Previous investi-
gations indicate that missense mutations often change PPIs,
suggesting that specific interaction perturbations underlie
distinct ND phenotypes (Sahni et al., 2015).
We found that the predicted disease protein modules, e.g.,
PDMO and ALSMO, contain distinct interactions (Figures 4E and
4F), indicating that specific molecular deficits and perturbations
are the origin of a particular disease phenotype. However, we
also found overlapping PPIs present in more than one of the
modules, suggesting therapeutic strategies might be relevant
for more than one ND (Ehrnhoefer et al., 2011). This is supported
by our cross-comparisons, indicating that genetic modifiers
(Chen and Burgoyne, 2012; Na et al., 2013) are linked to different
NDCPs in our computationally predicted disease subnetworks
(Figures 4A–4C). Our analysis also revealed that many other
known human disease proteins (ODAPs) are linked to NDCPs
(Figures 4G and 4H), suggesting that knowledge from other dis-
ease areas might stimulate ND-specific research. For example,
the transcriptional coactivator MKL1 involved in cancer develop-
ment is linked to many known NDCPs in the predicted modules
(Figures 4D–4F). In the brain, however, MKL1 function is critical
for dendritic spine maturation (Kaneda et al., 2018). A loss of
this function in AD brains, e.g., through abnormal aggregation
(Figure 5H), may contribute to disease development and
progression.
A large body of previous evidence points to abnormal aggre-
gation of NDCPs such as HTT, SNCA, tau, and TDP-43 as poten-
tial drivers of pathogenesis in NDs (Sami et al., 2017). Theoretical
investigations indicate that various aggregation-prone proteins
may be associated with NDs (Ciryam et al., 2015), suggesting
that protein aggregation is a more widespread phenomenon
than commonly appreciated. However, systematic experimental
studies with biosamples from ND patients to support these con-
siderations have been lacking. Here, we present experimental
evidence that various computationally predicted AD-associated
proteins, such as UBQLN1, FLNA, ATXN1, HSPA5, ERG2,
SNCA, andMKL1, are aberrantly aggregated in AD patient brains
(Figures 5H–5N), confirming that current assumptions underesti-
mate the relevance of the phenomenon. We hypothesize that the
initial formation of primary amyloid such as b-amyloid or tau may
trigger an aggregation cascade that over time involves multiple
proteins (Gidalevitz et al., 2006) and leads to synergistic dysfunc-
tion and toxicity in patient brains. However, different aggrega-
tion-prone proteins may precipitate independently, leading to
the accumulation of spatially distinct protein deposits inCell Reports 32, 108050, August 18, 2020 11
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aggregates in brains of AD patients has been described (Higashi
et al., 2007), whereas abnormal aggregation of ATXN1 in AD
brains has not been reported. Strikingly, loss of this protein
was shown to potentiate AD pathogenesis in mouse brains
(Suh et al., 2019), supporting our hypothesis that ATXN1 aggre-
gationmay contribute to ADpathogenesis. Mixed protein pathol-
ogies have been shown to be associated with more severe
symptoms in AD patients (James et al., 2016) and PD patients
(Irwin et al., 2013). A better understanding of the relationships
between aggregate pathologies and their associated clinical
phenotypes will be critical to clarifying the role of amyloidogenic
protein aggregates in disease.
Our strategy to create a PPI map for proteins involved in NDs
and to define potentially disease-relevant subnetworks and
protein modules will extend our current understanding of ND
mechanisms, like the identification of ARF-GEP100 as a generic
modulator of protein aggregation inmammalian cells and various
disease models (Figure 6). However, it is important that the pre-
sented PPI networkmap of NDs be regarded as neither complete
nor final. Many highly relevant disease proteins, like glucocere-
brosidase (GBA) and various Rab proteins (e.g., RAB7-L1),
have not been systematically screened, because cDNAs were
not available or they acted as autoactivators in the Y2H assays.
Further mapping, validation, and data integration efforts will
create an even more comprehensive PPI dataset for proteins
associated with NDs. To aid these efforts, NN1.0ext is a valuable
resource that contains unique information for detecting disease
modifiers, novel drug targets, and biomarkers for multiple NDs.STAR+METHODS
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nlm.nih.gov/homologene)
STRING database STRING RRID: SCR_005223 (https://string-db.org/)
Blat search genome database N/A https://genome.ucsc.edu/cgi-bin/hgBlat
GoldenPath (human genome) database N/A https://genome.ucsc.edu/
Gene Ontology (GO) database Gene Ontology RRID: SCR_002811 (http://www.
geneontology.org/)
Collection of differentially aging-related
expressed human genes
Lu et al., 2004 N/A
Collection of HTT-interacting proteins
from a Y2H/MS study
Kaltenbach et al., 2007 N/A
Collection of selected NDCPs This paper (Table S3) N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
Collection of selected ND modifiers This paper (Table S3) N/A
HI-II-14 PPI dataset Rolland et al., 2014 N/A
CORUM (protein complex dataset) CORUM (Ruepp et al., 2010;
Woodsmith and Stelzl, 2014)
RRID: SCR_002254 (https://mips.
helmholtz-muenchen.de/corum/)
Phosphosite (kinase-substrate PPI dataset) PhosphoSitePlus: Protein
Modification Site
(Hornbeck et al., 2015)
RRID: SCR_001837 (https://www.
phosphosite.org/homeAction.action)
Supersaturation scores of human proteins Ciryam et al., 2013 N/A
Protein set obtained from amyloid plaques Liao et al., 2004 N/A
Protein set obtained from neurofibrillary
tangles (NFTs)
Wang et al., 2005 N/A
Protein set obtained from Lewy bodies Xia et al., 2008 N/A
Experimental Models: Cell Lines
E.coli: Competent Mach1 cells Thermo Fisher Scientific Cat#C862003
S. cerevisiae: L40cca [MATa his3D200 trp1-910
leu2-3,112 ade2 LYS2::(lexAop)4HIS3 URA3::
(lexAop)8-lacZ GAL4 gal80 can1 cyh2]
Wanker et al., 1997; Goehler et al., 2004 N/A
S. cerevisiae: L40ccua [MATa his3D200 trp1-
901 leu2-3,112 LYS2::(lexAop)4-HIS3 ura3::
(lexAop)8-lacZ ADE2::(lexAop)8-URA3 GAL4
gal80 can1 cyh2]
Wanker et al., 1997; Goehler et al., 2004 N/A
Homo sapiens: HeLa cell line ECACC (Sigma-Aldrich) Cat#93021013; RRID: CVCL_0030
Homo sapiens: HEK293 cell line ECACC (Sigma-Aldrich) Cat#85120602; RRID: CVCL_0045
Experimental Models: Organisms/Strains
E. coli: OP50 strain N/A Acc. No.: PRJNA41499; Tax ID: 637912
D. melanogaster: GMR-GAL4/UAS-TDP-43 M337V Ritson et al., 2010 Line #1
D. melanogaster: y1w118 Juan Botas (The Hutch, Seattle, USA) N/A
D. melanogaster: GMRGAL4/CyO Juan Botas (The Hutch, Seattle, USA) N/A
D. melanogaster: UAS-Hsap\HTT336Q128[M64] Juan Botas (The Hutch, Seattle, USA) N/A
D. melanogaster: Elav-GAL4 Juan Botas (The Hutch, Seattle, USA) N/A
D. melanogaster: UAS-Hsap\HTT336Q128[F27B] Juan Botas (The Hutch, Seattle, USA) N/A
Homo Sapiens: Brain tissues Institute for Aging and Health,
Newcastle University (Newcastle upon
Tyne, UK)
N/A
pBTM116-D9 (derived from pBTM116) Clontech; Goehler et al., 2004 N/A
pACT4-DM (derived from pACT2) Clontech Cat#638822
pPA-RL-GW Trepte et al., 2015 N/A
pFL-V5-GW Trepte et al., 2015 N/A
pCFPHttex1Q49 This paper N/A
pV5mCherryLuc This paper N/A
pV5ARF-GEP100 This paper N/A
pTHW Kaltenbach et al., 2007 N/A
pmTq2-DEVD-mCit Gr€unberg et al., 2013 N/A
pGW-RL-PA Trepte et al., 2015 N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
pDONR221-NL Trepte et al., 2018 N/A
Additional plasmids and more information Trepte et al., 2018 Dataset EV1
Software and Algorithms
G2D (candidate genes to inherited diseases) tool Perez-Iratxeta et al., 2005 RRID: SCR_008190
Genie text mining tool Fontaine et al., 2011 http://cbdm-01.zdv.uni-mainz.de/
jfontain/cms/?page_id=6
MeSH (medical vocabulary resource) MeSH RRID: SCR_004750 (https://www.
nlm.nih.gov/mesh/index.html)
Visual Grid software Agennix AG N/A
GraphPad Prism GraphPad RRID: SCR_002798 (http://www.
graphpad.com)
Aida image analysis software Elysia-Raytest RRID: SCR_014440 (https://www.elysia-
raytest.com/en/cataloglight/c30aida-
mage-analysis-software)
R for statistical computing R Project for Statistical Computing RRID: SCR_001905
(https://www.r-project.org/)
Cytoscape software Shannon et al., 2003 RRID: SCR_003032
(https://cytoscape.org/)
NetworkAnalyzer (Cytoscape plugin) Assenov et al., 2008 N/A
PRINCE algorithm Vanunu et al., 2010 N/A





Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Erich
Wanker (erich.w@mdc-berlin.de).
Materials Availability
This study did not generate new unique reagents.
Data and Code Availability
The accession number for the binary PPIs of NN1.0ext reported in this paper (Table S2) is IntAct: IM-28217. The data have been sub-
mitted to the IMEx consortium (http://www.imexconsortium.org) through IntAct [Orchard et al., 2014] and are accessible under
https://www.ebi.ac.uk/intact/search/do/search?searchString=pubid:IM-28217.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cells, C. elegans and D. melanogaster models
For plasmid transformation experiments, competent E. coli Mach1 cells were routinely grown in flasks or microtiter plates with LB
ampicillin medium. Nematodes were maintained on E. coli OP50 seeded NGM plates. For transformation with plasmid DNA yeast
strains (L40ccua and L40cca) were grown in rich medium (YPD) supplemented with 2 % glucose. For transient transfection exper-
iments with plasmid DNAs, HeLa cells were cultivated in DMEM medium (Dulbecco’s Modified Eagle Medium, GIBCO 31885049)
containing L-glutamine, sodium pyruvate and 1 g/l D-glucose, supplemented with 10% FBS and 1% P/S. Cells were incubated at
37C with 5% CO2 in cell culture flasks. Then, cells were washed once with PBS and treated with trypsin/EDTA for two minutes, re-
suspended in medium and centrifuged for three minutes at 150 g. Finally, the cells were seeded into new cell culture flasks, 6-well
plates or 96-well microtiter plates according to maintenance or analyses intended.
For RNAi-mediated knockdown experiments nematodes were grown on NGM plates seeded with the E. coli HTT115 strains
carrying the L4440 plasmid encoding the respective C. elegans gene at 20C. For synchronization, gravid adults from one 10 cm
NGM plate were collected in a canonical tube and treated with 20% alkaline hypochlorite solution under vigorous agitation for
4 min. The eggs were then washed 3 times with cold 0.1 M NaCl solution. The eggs were allowed to hatch in M9 medium at 20C
for 22 h.Cell Reports 32, 108050, August 18, 2020 e4
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OPEN ACCESSThe D. melanogaster strain GMR-GAL4/UAS-TDP-43 M337V (line #1) was previously described (Ritson et al., 2010). Flies were
raised on standard diet. RNAi stocks were obtained from either the Bloomington Drosophila Stock Center (Indiana University, Bloo-
mington, IN, USA, RRID:SCR_006457) or the Vienna Drosophila Resource Center (RRID:SCR_013805). Drosophila lines used for
RNAi knockdown and co-expression experiments are listed in Table S4.
The fly line for expression of GFP (1521) was obtained from the Bloomington Drosophila Stock Center. The fly strains y1w118,
GMRGAL4/CyO, UAS-Hsap\HTT336Q128[M64], Elav-GAL4 and UAS-Hsap\HTT336Q128[F27B] were provided by Juan Botas
(Fred Hutchinson Cancer Research Center, Seattle, Washington). Transgenic flies harboring HTT partner proteins (Table S4) were
generated by BestGene Inc (Chino Hills, CA, USA). For all experiments, flies were kept at 25C on standard medium. The Information
about age and sex of the flies is not available.
METHOD DETAILS
Selection of ND-related target genes
For the selection and prioritization of target genes related to neurodegenerative diseases (NDs), we first generated 15 collections with
human genes (see below and Table S1). Targets were selected based on available literature information, high throughput experi-
mental datasets, data mining of genomic and drug target data and text mining of MEDLINE abstracts (https://pubmed.ncbi.nlm.
nih.gov/). We focused mainly on five diseases (AD, HD, PD, ALS and SCA1) but did not exclude available information related to other
NDs. Finally, using the available information a ranked list of genes related to NDs was generated. Each gene g of the collection cwas
scored with a subscore Rcg between 0 (not selected or not predicted relation) and 1 (high confidence selection or prediction):
Rcg ∊ [0,1]





where the collection weight Wc was defined as shown in Table S1.
When a high throughput dataset of size N (e.g., the total number of probes of a microarray dataset) was analyzed for a collection c













For the gene collection ProtAgg_TM the constant K = 1 e-30 was applied; for the gene collections ND_TM, ND_DifExp, ND_DrugT_TM
and Aging_DifExp (see details below and in Table S1), we applied K = 0.05. Through this data integration strategy, a ranked list of
3,711 potentially ND-associated genes was created (Table S1).
The Known_NDTs selection method is a manual selection by mutations from the literature on the following disease-causing genes
known to be related to the key NDs described above (sub score = 1 if selected, 0 otherwise): SNCA, APP, HTT, ATXN1, PARK2, SOD1
and PSEN1. In addition to known disease causing genes, the procedure includes a manual ranking of genes genetically related to
NDs from the OMIM database (sub score = 1 if considered very interesting, 0.75 if interesting, 0.5 if moderately interesting, 0.3 if
selected and 0 otherwise).
The manual method GenMod was used to select genes from the literature that have mutations associated to NDs (sub score = 1 if
selected, 0 otherwise).
With AggToxMod genes known to be disease modulators were manually selected from literature (sub score = 1 if
selected, 0 otherwise).
The HTT_Int method is a selection of HTT-interacting proteins from a study using high-throughput yeast two-hybrid screenings and
affinity pull down followed bymass spectrometry experiments. The HTT sub score is set to 1 if the genewas listed in the related article
(Kaltenbach et al., 2007), 0 otherwise.
The OrthMod method is a selection based on several studies of HD, PD and SCA modulators in human or animal models (mouse,
yeast, fly and worm). Relevant genes in a set of selected articles (Table S1, sheet ‘‘Studies OrthMod’’) were extracted and automat-
ically matched to the human orthologs using the Homologene database.
The sub score is set to 1 if the gene is a modifier, listed in the articles and if it has a human ortholog. The sub score is equal
to 0 otherwise.
The ND_ChrReg method is a set of gene predictions for the NDs of interest (Table S1, sheet ‘‘Datasets’’) using the G2D tool (Perez-
Iratxeta et al., 2005), except SCA1 due to missing information. G2D evaluates genes in the chromosomal region where the disease is
mapped to; it prioritizes them for a possible relation to the disease based on the phenotype of the disorder or their similarity to an
already known related gene. If a phenotype is linked to multiple loci, known or inferred interactions between proteins of two loci
each are also used. The sub score is the resulting gene score of G2D or 0 if the gene has no G2D score.
TheND_TMmethodused theGénie textmining algorithmof gene prioritization (Fontaine et al., 2011). The query for each diseasewas
done using corresponding MeSH (Medical Subject Headings; NCBI). As no MeSH term is specifically dedicated to SCA1, we used the
more general term ‘‘Spinocerebellar Ataxias’’ to produce the results. We selected genes associated to p values below 0.005. The sube5 Cell Reports 32, 108050, August 18, 2020
Resource
ll
OPEN ACCESSscore is a scaling of the returned p value between 0 and 1 (see calculation of Rcg above). Score = 1means that topics of articles related
to a gene over-represent at least one of the 5 NDs with very high confidence. Score 0 means that there is no over-representation.
The ND_TissESTs method is based on the EST database to have evidence on gene expression in tissues from the nervous system.
We used the GenBank database to select ESTs annotated to be expressed in the nervous system. EST tissue annotations were
matched to relevant MeSH terms. We used all MeSH headers and synonymous terms which depend on ‘‘Nervous System’’
(MeSH term ID starts with A08) in the hierarchy. Assignment of ESTs to genes was done by similarity search (Blat) on the human
genome (GoldenPath). We selected only hits with high score and percentage of identity (blat score/qSize R 95 and pid R 95%).
The sub score is set to 1 when ESTs were selected, 0 otherwise.
The ND_DifExp method is based on publicly available microarray datasets of ND-related human samples (Table S1, sheet ‘‘Micro-
arrays ND_DifExp’’). Each dataset was processed to extract differentially expressed genes between healthy and disease patients. No
SCA1-related datasets were found in the NCBI Geo database. The score is a scaling of the minimal p value between 0 and 1 (see
calculation of Rcg above). We selected p values below 0.005. Score 1 means that a gene is considered differentially expressed
(over- or under-expressed) with very high confidence. Score 0 means no differential expression.
The DrugBank method is based on the DrugBank database (Wishart et al., 2006) which is a bioinformatics and cheminformatics
resource that combines detailed drug data with comprehensive drug target information. At the time of download, the database con-
tained approximately 4,800 drug entries including > 1,350 FDA-approved small molecule drugs, 123 FDA-approved biotech (protein/
peptide) drugs, 71 nutraceuticals and > 3,243 experimental drugs. Additionally, more than 2,500 non-redundant protein (i.e., drug
target) sequences are linked to these FDA approved drug entries. We have set lists of drugs that target each gene. The specificity
of each drug decreases with its number of targets. Each drug related to a gene is scored as follows:
Drug specificity =
1ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
number of known gene targets
p
The final gene score is the maximum of observed scores of its related drugs. Low scores denote weakly specific drugs and high
scores denote very specific drugs.
The ND_DrugSideEff method is based on protein targets prediction of FDA (Food and Drug Administration) approved drugs.
Known drug targets were extracted from the manually curated protein-chemicals interaction databases MATADOR, DrugBank
and PDSP Ki databases. The prediction is based on a scoring scheme that evaluates the probability that a drug shares a direct target
with known PD-, AD- or ALS-related drugs. The scoring scheme is calculated given the similarity of side effects and the Tanimoto’s
2D structural similarity index. The sub score of a gene is themaximal value of the specificity of its predicted drugs that is calculated as
defined in the DrugBank method (see above). Scores are between 0 (bad) and 1 (good).
The ND_DrugT_TMmethod scores each human gene thanks to a list of drugs related to the gene and to NDs by using text mining of
MEDLINE abstracts. We have used a list of known ND drugs and related disease targets from DrugBank (Table S1, sheet ‘‘Drugs
ND_DrugT_TM’’). The best drug-ND associations were first evaluated and selected by Fisher’s exact tests (p values < 0.005) based
on co-occurrences of ND-related MeSH terms and drug names in Medline abstracts. P values were scaled from 0, no association
to 1, strong association (see calculation of Rcg above). Scores were multiplied by the drug specificity (as defined in the DrugBank
method). Then, the final gene score is the maximum of observed scores of its related ND drugs.
The ProtAgg_TM method used the Génie text mining algorithm (Fontaine et al., 2011) to predict human protein-coding genes
related to protein aggregation. The training set was composed of abstracts related to protein aggregation from a PubMed query
and compared to the rest of MEDLINE (Fontaine et al., 2011). The method selected 992 genes with uncorrected p values ranging
from 1*105 to 1.55*10158. The sub score was defined as the scaling of the p value (see calculation of Rcg above) so that a score 1
means very high confidence and score 0 means that there is no over-representation.
The IntGenMod method is based on Known_NDTs genes and used the UniHi database (http://www.unihi.org) to find interacting
proteins and the STRING database (https://string-db.org) to discover functionally related genes. We manually defined a scoring
scheme for UniHi genes that considers the number of related direct and indirect interactors within Known_NDTs genes, and a scoring
scheme for STRING genes that depends on the number of interactors (Table S1, sheet ‘‘Scores IntGenMod’’). Genes showing direct
interactions in UniHi with one or several Known_NDTs genes received the highest scores. A search in STRING was done for the best
27 Known_NDTs genes that have a sub score R 0.5. The overall score is the maximum of UniHi and STRING gene scores.
The Aging_DifExp method is based on genes differentially expressed between young (age% 42 years) and older (ageR 73 years)
people from a gene list provided in a published study (Lu et al., 2004). Post-mortem samples from the frontal pole of 30 individuals
ranging in age from 26 to 106 were analyzed using Affymetrix gene chips. The score is a discretization of the provided q-values.
Score 1 corresponds to a q-value equal to 0 and score 0.8 to a p value equal to 0.01. Score 0 means no differential expression.
Literature review for selected target genes
Textmining for the top 100 of the initially selected targets for the term ‘‘neurodegeneration’’ was done using theGénie algorithm (Fon-
taine et al., 2011). We assessed how often each of the selected target genes was found together with the term ‘‘neurodegeneration’’




Enrichment of binary interactomemaps [NN1.0, NN1.0ext and HI-II-14 (Rolland et al., 2014)] for functional relationships [shared Gene
Ontology (GO) terms] and co-complex memberships was determined. In addition, the number of known kinase-substrate interac-
tions found in the binary interaction maps was investigated.
The published datasets (Ruepp et al., 2010; Woodsmith and Stelzl, 2014) and (Hornbeck et al., 2015) were used for analysis. PPIs
were trimmed to interactions where both proteins were present in the binary interactomemaps for pairwise comparisons. The enrich-
ment was computed as the hypergeometric p value of the intersection between the examined PPI set and a gold standard set
(Figure 2A).
Prediction of disease-relevant proteins
To predict potential disease-relevant proteins such as NDCPs, ND modifiers or drug targets in NN1.0ext, a network propagation al-
gorithm was applied (Mazza et al., 2016; Vanunu et al., 2010). This approach starts from primarily defined priors (e.g., known NDCPs)
and a single initial parameter (alpha) that weighs the contribution of the network versus that of the priors. Here, we used a default
parameter alpha of 0.9 as recommended (Gottlieb et al., 2011; Vanunu et al., 2010). This value gives more weight to the network
over the prior values.
A quantitative propagation score for every protein in the network was calculated, which is an indication of its proximity to the prior
proteins. This scoring provides a ranking of the proteins, which we can evaluate using a receiver operating characteristic (ROC) curve
(Figures 2B–2D). To assess the significance of the ROC curve obtained, we compared it to 100 analogous curves that result from
applying the same procedure to 100 randomized networks with the same node degrees.
It should be noted that the propagation scores correlate with the vertex degree that is highest for the baits of the Y2H experiment.
Since these baits were chosen to be ND related, they intersect the lists of NDCPs and NDmodifiers that are shown in the Figures 2B
and 2C.
Construction of ND subnetworks and modules
Subnetworks and protein modules for the NDs AD, PD and ALS were constructed using a previously described propagation-based
algorithm (Mazza et al., 2016). Briefly, the computation starts from known priors (NDCPs, Table S3), which are available in the liter-
ature for each disease. The network’s proteins are then ranked with respect to the prior set using propagation, and their scores are
compared to those obtained by propagating random prior sets of the same size. By ranking the real score of every protein against its
random counterparts (excluding the random instances where this protein was selected as the prior), we obtained an empirical p value
for every protein in NN1.0ext, retaining only those at a 0.01 significant level. The generated PPI subnetworks were termed ADSN, PDSN
and ALSSN. The subnetworks induced on these significantly scoring proteins served as the input network for the prediction of highly
connected protein clusters (Mazza et al., 2016), here also termed ADMO, PDMO and ALSMO (Figures 4D–4F). High scoring clusters
were detected using an integer linear programming algorithm (Mazza et al., 2016) that optimizes the interaction density of a candidate
module as well as the scores of its member proteins. This process resulted in 4-5 protein clusters for each disease using the available
PPI information (Figures 4D–4F and S4A).
Data cross-comparisons
For systematic data cross-comparisons, we merged the genes of our computationally predicted disease subnetworks ADSN, PDSN
and ALSSN into one dataset. This dataset was then compared with published data from Na et al. (2013) and Chen and Burgoyne
(2012). In both publications so-termed genetic modifiers, i.e., genes that influence ND-related phenotypes in disease
models such as C. elegans, D. melanogaster and yeast were compiled in comprehensive datasets. We then mapped these
genes to their human orthologs and defined those that are present in NeuroNet1.0ext. Next, we determined the overlaps
between our computationally predicted gene set and the previously reported datasets (Na et al., 2013; Chen and Burgoyne,
2012; Figure 4A). To evaluate whether the observed overlaps can be expected by chance, we performed a hypergeometric
test, indicating that potential genetic modifiers are significantly enriched in our computationally predicted protein subnetworks
(p values < 0.01; Figure 4B).
Next, we investigated whether proteins that aggregate in patient brains are enriched in our disease-associated subnetworks. We
compared this dataset with related published data from Liao et al. (2004), Wang et al. (2005) and Xia et al. (2008); here, proteins asso-
ciated with amyloid plaques, neurofibrillary tangles and Lewy bodies were identified.
We found that 117 (15.4 %) out of the 762 proteins, which are aggregated in AD and PD patient brains, are present in our compu-
tationally predicted disease-associated subnetworks (Figures 5C–5E). To assess whether this overlap can be expected by chance, a
hypergeometric test was performed using the protein set of NN1.0ext as the protein universe. It revealed that potential aggregation-
prone proteins are significantly enriched in our predicted disease subnetworks (p value < 0.0001).
For the identification of disease-associated proteins, we first merged the proteins of our computationally predicted disease
modules ADMO, PDMO and ALSMO into one dataset. In addition to priors (Figure 4G), i.e., known NDCPs that were initially utilized
for module identification, our protein modules contain 56 non-prior proteins. These proteins were then mapped to the OMIM data-
base containing information for multiple genetic disorders. We found that 24 (42.9 %) proteins are present in OMIM. They were
termedOMIMdisease-associated proteins (ODAPs, Figure 4H). To evaluatewhether such a high number of proteins can be expectede7 Cell Reports 32, 108050, August 18, 2020
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OPEN ACCESSby chance, we performed a hypergeometric test using NN1.0 as the protein universe. This analysis indicated that ODAPs are signif-
icantly enriched in our computationally predicted protein modules (p value < 0.0001).
Supersaturated, aggregation-prone proteins
Based on the database provided by Ciryam et al. (2013), that contains supersaturation scores assigned to proteins of the human
proteome, we compared the average supersaturation score of the whole proteome with the average score of the predicted proteins
in the subnetworks and modules. The supersaturation score sf measures the aggregation tendency of proteins that are initially
folded, while the supersaturation score su measures that of unfolded proteins. We calculated the median of the supersaturation
scores for the proteome and the proteins in the predicted disease-specific subnetworks and protein modules. The statistical signif-
icance was assessed by the Mann-Whitney U test with Bonferroni-corrected p values. GraphPad Prism (GraphPad,
RRID:SCR_002798) was used to create the boxplots. They extend from the lower to the upper quartiles, with the internal lines refer-
ring to the median values (Figures 5A and 5B).
To investigate the abundance of co-aggregating proteins from ND patient brains in our predicted subnetworks, we analyzed pro-
tein sets obtained from amyloid plaques (Liao et al., 2004), neurofibrillary tangles (NFTs) (Wang et al., 2005) and Lewy bodies (Xia
et al., 2008). For comparison, the abundance of the patient brain proteins in the proteome was also analyzed. The statistical signif-
icance was assessed with a Fisher’s exact test with Holm–Bonferroni corrections (Figures 5C–5E).
Automated Y2H interaction screening
The MATa yeast strain L40cca was individually transformed with pACT4-DM-based plasmids encoding prey proteins to create a
prey-matrix for interaction mating. The resulting yeast clones were arrayed in 384-well microtiter plates. The pBTM116-D9-based
plasmids encoding bait proteins were transformed into the MATa yeast strain L40ccua. The activation of the reporter genes HIS3,
URA3, and lacZ through the production of bait proteins (autoactivation tests) was investigated systematically. Only yeast strains
that express reporter non-autoactivating bait proteins were utilized for systematic interaction screening (Stelzl et al., 2005). Liquid
cultures of MATa yeast strains (preys) were replicated in 384-well microtiter plates using a pipetting robot (Tecan Freedom EVOware)
and mixed with MATa strains expressing bait proteins. Then, yeast mixtures were transferred onto YPD agar plates for interaction
mating using a spotting robot (Kbiosystems K4). After incubation for 48 h at 30C, the resulting colonies were automatically picked
from agar plates and transferred into 384-well microtiter plates containing SDII (-Leu-Trp) liquid medium. From these plates, they
were spotted onto SDII (-Leu-Trp) agar to select for diploid yeasts carrying both – bait and prey - vectors. After additional incubation
for 48 h at 30C, diploid yeast clones were spotted onto SDIV (-Leu-Trp-Ura-His) agar to detect PPIs through growth selection. In
addition, yeast clones were spotted onto high density Nylon membranes placed on top of SDIV agar plates to perform b-galactosi-
dase assays. After incubation for 3 to 4 days at 30C, grown colonies were fractured by liquid nitrogen and b-galactosidase activity
was determined using X-Gal as a substrate. Digital images were taken from agar plates and from high density Nylon membranes and
analyzed using the Visual Grid software (GPC Biotech).
PPI detection in cells using DULIP and LuTHy
The procedure for detecting binary PPIs in mammalian cells using DULIP has been described in detail (Trepte et al., 2015). Briefly,
HEK293 cells (ECACC, Cat#85120602, RRID:CVCL_0045) were reversely transfected in 96-well microtiter plates at a density of
3.75 3 104 cells per well. 48 hours post transfection, cells were lysed in 100 mL HEPES lysis buffer [50 mM HEPES, 150 mM
NaCl, 10% glycerol, 1% NP-40, 0.5% deoxycholate, 20 mM NaF, 1.5 mM MgCl2, 1 mM ethylenediaminetetraacetic acid, 1 mM
DTT, 1 U Benzonase, protease inhibitor cocktail (ethylenediaminetetraacetic acid free; Roche) and 1 mM PMSF] for 30 min at
4C. Production of luciferase-tagged fusion proteins was monitored by measuring the respective activities in crude cell lysates in
384-well microtiter plates. 10 mL of cell lysate was added to 20 mL phosphate-buffered saline (PBS), and 10 min after the addition
of 10 mL Dual-Glo luciferase reagent (Promega), the firefly activity (FLIN) was measured using an Infinite
M1000 (Tecan) plate reader. To stop the FL activity and to measure the RL activity (RLIN), we added 10 mL of the Dual-Glo Stop and
Glo reagent (Promega) andmeasured the activity after 15min of incubation. In parallel, 50 mL of the cell lysate was incubated for 3 h at
4C in IgG pre-coated 384-well microtiter plates. Plates were coated with sheep gamma globulin (Dianova), blocked with 1% bovine
serum albumin in carbonate buffer (70 mM NaHCO3 and 30 mM Na2CO3, pH 9.6) before they were incubated with rabbit anti-sheep
IgGs (Jackson ImmunoResearch Labs Cat#313-005-003; RRID:AB_2339937) overnight. After cell lysate incubation, all wells were
washed three times with HEPES lysis buffer before 30 mL of PBS was added to each well. Measurement of firefly (FLOUT) and Renilla
(RLOUT) luminescence activity was performed as described above using an Infinite M1000 (Tecan) plate reader.
The double-readout bioluminescence-based two-hybrid technology (LuTHy) for testing binary interactions has been described
(Trepte et al., 2018). Reverse transfection of HEK293 cells in white 96-well microtiter plates (Greiner, 655983) at a density of 4.0–
4.5 3 104 cells per well was performed. Plasmids encoding donor and acceptor proteins were transfected at a 1:10 to 1:20 ratio,
with 5–10 ng DNA for the donor and 100 ng for the acceptor. The fluorescence of mCitrine was measured 48 h after transfection
in intact cells (Ex/Em: 500 nm/530 nm). Then, coelenterazine-h (NanoLight, 301 or pjk, 102182) was added to a final concentration
of 5 mM. The cells were incubated for an additional 15 min and the total, short-WL and long-WL luminescence was measured. Here,
fluorescence and luminescence were measured using the Infinite microplate readers M200, M1000, or M1000Pro (Tecan) using
the BLUE1 (370–480 nm) and the GREEN1 (520–570 nm) filters at 1,000 ms integration time. After this step, luminescence-basedCell Reports 32, 108050, August 18, 2020 e8
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cence (mCitIN) and luciferase activity (NLIN) in crude cell lysates in white, small volume 384-well microtiter plates (Greiner, 784074).
We added 5 ml coelenterazine-h to 5 ml of cell lysates to a final concentration of 10 mM and measured the luminescence activity as
before in a microplate reader with 100 ms integration time. We coated small-volume 384-well microtiter plates (Greiner, 784074) the
day before use with sheep gamma globulin (Jackson ImmunoResearch, 013-000-002) in carbonate buffer (70 mM NaHCO3, 30 mM
Na2CO3, pH 9.6) for 3 h at room temperature. Then, 15 ml cell lysate was incubated for 3 h at 4C in the IgG-coated 384- well plates.
Wells werewashed 3 timeswith lysis buffer andmCitrine fluorescence (mCitOUT) wasmeasured as above. Finally, 15 ml of PBSbuffer
containing 10 mM coelenterazine-h was added to each well and the luminescence activity (NLOUT) was measured as described
above.
Selection of predicted AD-associated proteins
We created a list of all proteins of the AD module using Microsoft Excel and added random numbers. Based on these numbers, we
randomly selected 15 proteins for validation experiments. After eliminating proteins for which no specific antibodies could be iden-
tified by SDS-PAGE and immunoblotting (Table S6), 7 remaining proteins and 3 control proteins were assessed by filter retardation
assays.
Selection of predicted TDP-43 modulators
We created a list of all TDP-43 interacting proteins from the Y2H studies using Microsoft Excel and added random numbers. Based
on these numbers we randomly select 20 proteins for the validation experiments. After sorting the list for these numbers and elim-
inating known TDP-43 modulators, 15 remaining proteins were assessed experimentally.
Knockdown of target genes in D. melanogaster
We conducted our RNAi screen in a Drosophila model expressing TDP-43 with the mutation M337V under the control of the GMR-
Gal4 driver. The genotype for these transgenic flies has been described (Ritson et al., 2010). Phenotypic analysis of the Drosophila
eye was performed by crossing the TDP-43 flies to double-stranded UAS-RNAi lines (obtained from the Vienna Drosophila Resource
Center). A total of 136 genes were selected for modifier screening. This includes 77 genes from the NN1.0ext interaction dataset and
78 TDP-43 interaction partners from a previously published study (Freibaum et al., 2010), of which 19were also identified in NN1.0ext.
In total, 232 RNAi lines were systematically screened (1-3 RNAi lines per gene). Eye degeneration phenotypes were scored on a scale
from 0-14 with 7 representing the basal phenotype. Phenotypes were examined 24-48 h after eclosion (Figures 3B and 3C).
Knockdown of target genes in C. elegans
For RNAi-mediated knockdowns of target genes, nematodes were placed as L1 larvae onto RNAi plates (containing 1 mM IPTG) and
moved onto fresh plates every second day to separate them from their progeny. The aggregation-propensity of disease-associated
polypeptides tagged with fluorescent proteins (e.g., TDP-43-M337-YFP, SYN-YFP, Q35-YFP or Luciferase_R188Q_R216Q-YFP)
was assessed by fluorescence microscopy 1-5 days after the knockdown of target genes with RNAi was initiated. For imaging, nem-
atodes were mounted onto 2% agarose (Sigma) pads on glass slides and immobilized with 2 mM Levamisole (Sigma). DAPI staining
was carried out immediately before mounting the nematodes by incubating them in DAPI solution (final concentration: 100 ng/ml) for
30 min. Images were taken on a Leica SP5 and a Zeiss LSM780 confocal microscope.
Analysis of retina degeneration in flies
For analysis of retina degeneration (Stroedicke et al., 2015) heads of 2-3 day old females were fixed for 48 h in Bouin’s fixative (Sigma-
Aldrich, St. Louis, MO, USA). Vertical 10 mm semi-thin paraffin sections were produced without histological staining. The absolute
retina extension was measured using standard light microscopy. 5-29 females were analyzed per genotype.
Protein aggregates in patient brains
Human postmortem brain tissue samples were obtained from the Newcastle Brain Tissue Resource (NBTR), Newcastle University,
UK. Frozen tissue derived from temporal cortex was weighted and homogenized in a 10-fold excess (w/v) of ice cold 50mM Tris-HCl
pH 7.5, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 0.25 U/ml Benzonase and a complete protease
inhibitor cocktail using a schuett homogen plus (schuett-biotec GmbH, Germany) semi-automatic homogenizer (700 rpm). After incu-
bating the homogenate for 30 min at 4C with rotation, it was centrifuged for 20 min at 1,500 x g at 4C to remove cell debris. The
supernatant was then transferred to a new tube and the protein concentration was determined with the Pierce BCA assay (Thermo
Fisher Scientific, Germany) using BSA as a standard. For analysis with filter retardation assays, protein homogenates prepared from
frozen brain tissues of AD patients and healthy controls were filtered through a cellulose acetate membrane with a pore size of 0.2 mm
(GE Healthcare Life Sciences, Germany). After washing the membrane with 1x PBS (13.7 mM NaCl, 0.27 mM KCl, 1 mM Na2HPO4,
0.2 mM KH2PO4, pH 7.4), it was blocked for 30 min with 3% skimmed milk (Sigma-Aldrich, Germany) in 1x PBS containing 0.05%
Tween-20 (PBS-T). Then, the membrane was incubated over night with the primary antibody diluted in 3% skimmed milk PBS-T.
Subsequently, the membrane was washed 3 times for 10 min in PBS-T, incubated for 15 min in 3% H2O2 and washed 3 times for
5 min in PBS. Then, the membrane was incubated with the secondary peroxidase-conjugated anti-mouse antibody for 1 h ate9 Cell Reports 32, 108050, August 18, 2020
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using ChemiGlow (Biozym Scientific GmbH, Germany). Chemiluminescence was detected with a FujiFilm LAS-3000 imager and im-
ages were quantified using the Aida image analysis software (Elysia-raytest, Germany, RRID:SCR_014440).
For the detection and quantification of CFP-Httex1Q49 aggregates in HeLa cells (ECACC, Cat#93021013; RRID:CVCL_0030) they
were washed once with PBS and lysed in buffer containing 50 mM Tris pH 8, 1 mM EDTA, 100 mM NaCl, 5 mM MgCl2, 1% NP40,
protease inhibitor cocktail and benzonase. Then, 30 ml of each cell lysate (20 mg of total protein) was supplied to cellulose acetate
membrane in triplicates, filtered and washed with 100 ml of 0.1% NP40. Membranes were blocked for 30 minutes in 3% milk-
PBS-0.05 % Tween-20 at room temperature. Incubation of membranes with primary antibodies (anti V5 or anti GFP) was carried
out at 4C with mild shaking overnight, whereas the secondary POD-labeled antibody was applied for 1 h at room temperature.
For quantification of chemiluminescence signals, the Aida image analysis software was utilized (Raytest, Germany).
Knockdown of MO2B7.5 (IQSEC1) in C. elegans
The gene knockdownwas repeated in two independent experiments as described above.Wormswere collected, RNAwas prepared
and used for Real Time PCR to determine the amounts of MO2B7.5 transcripts in control and RNAi treated animals. The results are
shown in Figures S3D and S3E.
qRT-PCR with RNAi treated C. elegans strains
The Bristol N2 strain was grown on RNAi plates supplemented with 1 mM IPTG, and seeded with HT1551 E. coli expressing either ds
RNA against IQSEC1 (Ahringer library gene: M02B7.5, Source BioScience) or the empty vector L4440, as a control. Nematodes were
synchronized via alkaline hypochlorite treatment and left to grow until gravid adulthood, approximately 4 days at 20C. On day 4,
nematodeswerewashed off plates andwashed 3 times inM9. After supernatant removal, nematode pellets were snap frozen in liquid
nitrogen and stored at 80C. For RNA extraction worm pellets were thawed on wet ice. To disrupt the cuticle of the worms the
freeze-thaw cycle was repeated five times, followed by disruption of the worm pellet by a 19-gauge syringe. Total RNAwas extracted
using Trizol reagent (Invitrogen/Thermo Fisher Scientific, Waltham, MA, USA) and the NucleoSpin RNA kit (Macherey-Nagel, D€uren,
Germany) as described (Kirstein et al., 2017). Two mg of RNA was reverse-transcribed using the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems/Thermo Fisher Scientific, Waltham, MA, USA). For quantitative RT-PCR, 10 ng of cDNA
was incubated with 6 ml SYBR Green PCR Master Mix (Applied Biosystems/Thermo Fisher Scientific, Waltham, MA, USA) and
3.96 pmol per primer in a total volume of 12 ml. The following primers were used:
IQSEC1 (Pair 1): 50-GGTGGAATGCAACTGGCTC-30 (forward) and 50-CTCCGCATCTTGCATCGAG-30 (reverse);
IQSEC1 (Pair 2): 50-GTGCTCGAGCGAAGATATGG-30 (forward) and 50-CATAATACAGTACTCGCGCCACG-30 (reverse);
cdc-42 (control gene): 50-AAACTTGTCTCCTGATCAGCT-30 (forward) and 50-TACTGTGACGGCGTAATTGT-30 (reverse).
Real-time PCR was performed using the ViiA 7 real-time PCR system (Applied Biosystems). Samples were measured in triplicates
and normalized to the cdc-42 housekeeping gene. Quantification was performed using the DCt method and the QuantStudio real-
time PCR Software v1.3.
Co-transfection of HeLa cells
Reverse transfection was applied in a 96-well plate format. For single and co-transfection experiments, 200 ng of each plasmid
(pCFPHttex1Q49, pV5mCherryLuc or pV5ARF-GEP100) were used per well. 0.825 ml PEI (stock concentration of 10mg/ml) wasmixed
in 1 mL OptiMEM, appropriate amounts of plasmids were added and incubated for 20 min at room temperature. 50 ml of these mix-
tures were split into triplicates and 6x104 cells were spread in 150 ml growth medium per well.
QUANTIFICATION AND STATISTICAL ANALYSIS
GraphPad Prism, Cytoscape (RRID:SCR_003032), MS-Excel and R (R Project for Statistical Computing, RRID:SCR_001905) were
used for data analysis and graphical representation. Statistical parameters including the value of n (number of independent exper-
imental replications), the definition of precision measures arithmetic mean ± SEM along with the significance are reported in the fig-
ures and figure legends. Data were judged to be statistically significant when p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) and p < 0.0001
(****). Specified statistical tests are described in the method details.Cell Reports 32, 108050, August 18, 2020 e10
